Galenea Corp. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 21 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Galenea Corp. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Galenea Corp. - Product Pipeline Review - 2015', provides an overview of the Galenea Corp.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galenea Corp.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Galenea Corp. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Galenea Corp.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Galenea Corp.'s pipeline products

Reason to Buy

- Evaluate Galenea Corp.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Galenea Corp. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Galenea Corp.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Galenea Corp. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galenea Corp.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Galenea Corp. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Galenea Corp. Snapshot 4
Galenea Corp. Overview 4
Key Information 4
Key Facts 4
Galenea Corp. - Research and Development Overview 5
Key Therapeutic Areas 5
Galenea Corp. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Galenea Corp. - Pipeline Products Glance 9
Galenea Corp. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Galenea Corp. - Drug Profiles 10
Small Molecule for Huntington's Disease 10
Product Description 10
Mechanism of Action 10
R&D Progress 10
Small Molecules to Agonize 5-HT2C Receptor for Obesity 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Small Molecules to Target 5-HT2C and 5-HT6 Receptor for Schizophrenia 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Galenea Corp. - Pipeline Analysis 14
Galenea Corp. - Pipeline Products by Target 14
Galenea Corp. - Pipeline Products by Molecule Type 15
Galenea Corp. - Pipeline Products by Mechanism of Action 16
Galenea Corp. - Recent Pipeline Updates 17
Galenea Corp. - Dormant Projects 18
Galenea Corp. - Locations And Subsidiaries 19
Head Office 19
Appendix 20
Methodology 20
Coverage 20
Secondary Research 20
Primary Research 20
Expert Panel Validation 20
Contact Us 20
Disclaimer 21

List of Tables

Galenea Corp., Key Information 4
Galenea Corp., Key Facts 4
Galenea Corp. - Pipeline by Indication, 2015 6
Galenea Corp. - Pipeline by Stage of Development, 2015 7
Galenea Corp. - Monotherapy Products in Pipeline, 2015 8
Galenea Corp. - Preclinical, 2015 9
Galenea Corp. - Pipeline by Target, 2015 14
Galenea Corp. - Pipeline by Molecule Type, 2015 15
Galenea Corp. - Pipeline Products by Mechanism of Action, 2015 16
Galenea Corp. - Recent Pipeline Updates, 2015 17
Galenea Corp. - Dormant Developmental Projects,2015 18